Iveric Bio receives FDA approval for avacincaptad pegol intravitreal solution for treatment of geographic atrophy
The company noted in a news release that avacincaptad pegol intravitreal solution, a new complement C5 inhibitor, is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials. (Image courtesy of Adobe Stock) Astellas Pharma Inc. announced today … Read more